Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

CEL-SCI net loss decreases to $17.6 million for fiscal year 2012

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2012.

14 Dec 2012

SLU researchers to study physiological and biochemical functions in lupus

Two researchers at Saint Louis University's division of rheumatology in the department of internal medicine have been awarded a $1.8 million NIH grant to study the physiological and biochemical functions in lupus, an autoimmune disease, and develop possible new medications for its treatment.

14 Dec 2012

Amgen declares $0.47 per share dividend for first quarter 2013

Amgen announced that its Board of Directors today declared a $0.47 per share dividend for the first quarter of 2013.

14 Dec 2012

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).

13 Dec 2012

Health systems must be more ‘adherence-friendly’

Heath system strategies must be appropriately designed to help narrow persistent racial/ethnic gaps in the use of antihypertensive therapy, say researchers.

13 Dec 2012

Heartbeat Experts announces increased revenue and expanded clients in emerging markets

Heartbeat Experts, the global leader in stakeholder management solutions for the life sciences industry, announced today increased revenue and expanded clients across Brazil, Russia, China, India and Korea. Heartbeat Experts' reported combined revenue from these markets grew 50% in the third quarter of 2012.

13 Dec 2012

Patients with multiple sclerosis have low levels of Egr2/3 protein in T lymphocytes

Researchers from Queen Mary, University of London have discovered that two proteins which are believed to play a key role in controlling the body's immune response are found in lower levels in T lymphocytes from patients with multiple sclerosis (MS).

13 Dec 2012

Dantrolene may help combat Duchenne muscular dystrophy in boys

Drugs are currently being tested that show promise in treating patients with Duchenne muscular dystrophy (DMD), an inherited disease that affects about one in 3,600 boys and results in muscle degeneration and, eventually, death.

13 Dec 2012

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New Drug Application (NDA) for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients.

13 Dec 2012

Moximed commences KineSpring System clinical trial in knee osteoarthritis

Moximed, Inc. announced today that the KineSpring System, an implantable medical spring that works by unloading the weight on the diseased knee joint, has been successfully implanted in the first patient enrolled in its US clinical study, SOAR.

11 Dec 2012

Lenalidomide effective alternative in lupus

The thalidomide derivative, lenalidomide, is a “safe” and effective treatment in refractory cutaneous lupus erythematosus patients, although three-quarters of patients experience clinical relapse after the drug is withdrawn, say Spanish researchers.

11 Dec 2012

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

11 Dec 2012

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced new data from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145, the company's potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies.

11 Dec 2012

CYP2J2 implicated in preeclampsia

Study findings suggest that uteroplacental cytochrome P450 subfamily 2J polypeptide 2 overexpression contributes to preeclampsia.

10 Dec 2012

Amgen signs definitive agreement to acquire deCODE Genetics

Amgen and deCODE Genetics today announced that the companies have entered into a definitive agreement under which Amgen will acquire deCODE Genetics, a global leader in human genetics, headquartered in Reykjavik, Iceland.

10 Dec 2012

Physician's Technology launches WilloMD iLaserX device

The Italian Renaissance sculptor Michelangelo once declared "everything hurts". Baby boomers are more active than ever and stress their joints. Millions rely on dangerous pain meds and injections to stay active. Pain medication and injections can be dangerous and even lethal. Popular therapeutic pain laser technology offers hope but is not practical for home use and is out of reach of a vast patient population.

10 Dec 2012

$Orthoses improve pain, balance in fracture-prone elderly$

Orthoses improve pain, balance in fracture-prone elderly

Short-term use of foot orthoses reduces pain and disability in elderly women with osteoporosis, results of a randomized clinical trial indicate.

6 Dec 2012

Galectins play an important role in development of osteoarthrosis

Inflammatory joint disease (arthritis) is affecting more and more, and especially older, people. In a recent survey by Statistik Austria, 39 per cent of people over the age of 60 stated that they have a form of arthritis. One particular form of the condition is osteoarthrosis, which is wear and tear on the joints.

6 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Viewpoints: David Brooks' formula to avoid Cliff; Krugman says control costs, don't cut coverage

Republicans should go to the White House and say they are willing to see top tax rates go up to 36 percent or 37 percent and they are willing to forgo a debt-ceiling fight for this year.

5 Dec 2012